Mechanism of IDH1-R132H mutation in T cell acute lymphoblastic leukemia mouse model via the Notch1 pathway.

Tissue Cell

Department of Hematology, The Sixth Affiliated Hospital of Wenzhou Medical University, No. 15, Dazhong Road, Liandu District, Lishui, Zhejiang 323000, China. Electronic address:

Published: February 2022

T-cell acute lymphoblastic leukemia (T-ALL) is a clonal malignant disease. Isocitrate Dehydrogenase 1-R123 (IDH1-R132 H) is related to T-ALL progression. This study explored the role of IDH1-R132H in T-ALL. Molt-4 cells with IDH1-R132H mutation were constructed by retroviral transfection of IDH1-R132H and T-ALL xenotransplantation mouse model was established by injection of Molt-4 cells through the tail vein. Infiltration of the liver, spleen, and bone marrow and the percentage of CD45-positive T-ALL cells in them were detected. Cell proliferation, apoptosis, and invasion were evaluated after the intervention of Notch1, PTEN, or PI3K expression. The leukocyte number was increased, the spleen was enlarged, infiltration in bone marrow, spleen, and liver tissue was worsened and the percentage of hCD45-positive T-ALL cells was increased by IDH1-R132H mutation, which promoted T-ALL deterioration. IDH1-R132H mutation promoted proliferation, invasion, and inhibited apoptosis of T-ALL cells, which were reversed by inhibition of Notch1. IDH1-R132H mutation upregulated HES1 expression and downregulated PTEN expression by activating the Notch1 pathway, while inhibition of Notch1 reversed these changes. PTEN inhibited the PI3K/AKT pathway activation. PTEN overexpression reversed IDH1-R132H mutation effect on promoting malignant behaviors of T-ALL cells. IDH1-R132H mutation inhibited PTEN expression by activating the Notch1/HES1 pathway, activated the PI3K/AKT pathway, thus promoting malignant behaviors of T-ALL cells.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tice.2021.101674DOI Listing

Publication Analysis

Top Keywords

idh1-r132h mutation
28
t-all cells
20
t-all
10
acute lymphoblastic
8
lymphoblastic leukemia
8
mouse model
8
notch1 pathway
8
idh1-r132h
8
idh1-r132h t-all
8
molt-4 cells
8

Similar Publications

Unlabelled: QUESTIONS AND RECOMMENDATIONS FROM THE PRIOR VERSION OF THESE GUIDELINES WITHOUT CHANGE: TARGET POPULATION: Adult patients (age ≥ 18 years) who have suspected low-grade diffuse glioma.

Question: What are the optimal neuropathological techniques to diagnose low-grade diffuse glioma in the adult?

Recommendation: Level I Histopathological analysis of a representative surgical sample of the lesion should be used to provide the diagnosis of low-grade diffuse glioma. Level III Both frozen section and cytopathologic/smear evaluation should be used to aid the intra-operative assessment of low-grade diffuse glioma diagnosis.

View Article and Find Full Text PDF

Targeting the mutation in gliomas by CRISPR/Cas precision base editing.

Neurooncol Adv

November 2024

Laboratory of Molecular Neuro-Oncology, Department of Neurology, Clinical Neuroscience Centre, University Hospital and University of Zurich, Zurich, Switzerland.

Background: Gliomas, the most frequent malignant primary brain tumors, lack curative treatments. Understanding glioma-specific molecular alterations is crucial to develop novel therapies. Among them, the biological consequences of the isocitrate dehydrogenase 1 gene mutation ( ) remain inconclusive despite its early occurrence and widespread expression.

View Article and Find Full Text PDF

Mutations in IDH1 and TP53 have a significant impact on glioma prognosis and progression; however, their roles in tumor cell invasion in terms of interactions with particular components of the extracellular matrix (ECM) are still unclear. Using gene editing protocol based on CRISPR-Cas 9 with cytidine deaminase, we introduced point mutations into U87MG glioblastoma cells to establish modified cell lines with heterozygous IDH1 R132H, homozygous TP53 R248Q and heterozygous IDH1 R132H, homozygous TP53 R248Q genotypes. A comparative study of cell migration on major ECM components was carried out by high-content microscopy.

View Article and Find Full Text PDF
Article Synopsis
  • This study focuses on the classification of glioma cases at Lagos University Teaching Hospital, utilizing the 2021 WHO brain tumor classification that combines histomorphology and molecular features, despite limited resources.
  • Of the 56 brain tumor cases examined, 52 were assessed, revealing that 35% of the initial diagnoses changed after applying the WHO criteria, with some diagnoses being upgraded and others downgraded.
  • The results emphasize the importance of molecular testing in improving brain tumor diagnoses in resource-limited settings like Nigeria and highlight the challenges faced in global health disparities in neuro-oncology.
View Article and Find Full Text PDF

Ollier Disease, Acute Myeloid Leukemia, and Brain Glioma: IDH as the Common Denominator.

Cancers (Basel)

September 2024

Department of Neurosciences, Division of Neurosurgery, Policlinico "G. Rodolico-S. Marco", University Hospital, 95123 Catania, Italy.

Article Synopsis
  • - The study explores the connection between Ollier disease (OD), acute myeloid leukemia (AML), and brain glioma (BG), which are distinct types of tumors but can occur in the same patient, and aims to find shared molecular pathways for potential treatment.
  • - A systematic literature review was conducted, revealing that thirty-three patients with both OD and BG were identified in previous studies, and only one documented case linked OD with AML—our case included all three diseases.
  • - The IDH R132H mutation was identified as a common genetic alteration in all three types of tumors, suggesting that targeted therapies using IDH1 inhibitors could provide new treatment options, although further research with larger groups is needed to validate these findings.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!